Bluepha Nets ￥10M in Series A+ Funding Round

According to VCBeat, Bluepha, a biotechnology company focused on the innovation and application of synthetic biology in molecules and materials, has recently completed Series A+ round, led by Green Pine Capital. Proceeds from the fresh funding will be used for the digitalization of the process of microbial design, fabrication, testing, and industrialization of existing product pipelines. Probe Capital continued to act as the financial advisor.

So far, Bluepha has raised four rounds of financing since its establishment at the end of 2016.

Established in 2016, Bluepha has a unique gene elements technology platform, which meets the need for molecular and material innovation in the medical, environmental protection, and consumer fields, opening the global market with hundreds of billions of dollars.

Bluepha is the first synbio startup founded by iGEMers in the Chinese iGEM (International Genetically Engineering Machine Competition) community. With the power of synthetic biology, the company enables the precise design of microorganism nano-factory to achieved the whole manufacturing processes under a microscope. 

In October 2019, Bluepha signed a strategic cooperation agreement with state-owned chemical company Sinochem International in Tsinghua University, to jointly promote the industrialization of PHA, a biodegradable material, which is important progress in the industrialization of synthetic biotechnology in China.

Synthetic biology, also known as engineering biology, is a new interdisciplinary area that involves the application of engineering principles to biology, aiming at the (re-)design and fabrication of biological components and systems. It has the potential to solve the challenges the modern society facing in the fields of energy, materials, health, and sustainable development. Cell factories, a research direction of synthetic biology, are commonly microbial organisms utilized for bioconversion of renewable resources to bulk or high-value chemicals.

Bluepha is building an automated assembly line for developing cell factories. It is gradually using artificial intelligence to replace the manual works of analysis of experimental data, generation of hypotheses, and planning of experiments. Holog, a self-developed system by Bluepha, can store and analyze all experimental process data.

Founded in 2007, Green Pine Capital is one of the most time-honored venture capital institutions in China, with rich experience in biomedicine, new energy and materials, advanced manufacturing, artificial intelligence, and other fields. The company not only provides funds for the invested enterprises, but also provides high-quality post-investment services and integrated resources. Green Pine Capital manages funds of ten billion yuan and has invested more than 7 billion yuan.